The Simoa® Human Neurology 4-Plex E (N4PE) assay concurrently detects four biomarkers in EDTA plasma and CSF. These targets include amyloid beta 40 (Aβ40), amyloid beta 42 (Aβ42), Glial Fibrillary Acidic Protein (GFAP), and Neurofilament light (NfL).

The Neuro 4-Plex E kit features new amyloid beta 40 and amyloid beta 42 assays designed for highly sensitive and specific measurement of full-length amyloid beta 1-42 and amyloid beta 1-40 concentrations. This enhanced specificity for full-length amyloid beta 1-42 and amyloid beta 1-40 is anticipated to be increasingly valuable for targeting specific amyloid-beta isoforms and for target engagement in forthcoming clinical trials.

Application and intended use

The Simoa® Human Neurology 4-Plex E (N4PE) assay measures four biomarkers in EDTA plasma and CSF simultaneously. These biomarkers are known to be relevant for studying neurodegeneration and brain injury. They are also useful for monitoring the effectiveness of drug discovery and development for neurological diseases.

Compatible instruments

  • Advantage Plus: HD-X
  • Advantage: HD-1/HD-X

Kit contents

The assay kit contains all the essential reagents and controls needed to conduct 96 tests, ensuring ease of use and compatibility with different sample types.

Other Equipment by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.